Mounjaro vs Ozempic: How Tirzepatide and Semaglutide Compare

Mounjaro vs Ozempic: How Tirzepatide and Semaglutide Compare

Mounjaro (tirzepatide) and Ozempic (semaglutide) are the two most prescribed weight-loss and type-2-diabetes injections in 2026. They look similar on the surface — both are weekly injections, both blunt appetite, both reliably lower blood sugar — but they are different molecules with different mechanisms and meaningfully different results in head-to-head trials.

This guide compares them on the things that actually matter to patients: weight loss, blood sugar, side effects, dose escalation, cost and what to track. For the full picture of monitoring treatment over time, the BodySynk GLP-1 tracker is the place to start.

The short answer

In the largest head-to-head trial to date (SURMOUNT/SURPASS-style direct comparisons), tirzepatide produced more weight loss and slightly more HbA1c reduction than semaglutide at comparable doses, with a broadly similar side effect profile. That does not automatically make it the right drug for you — tolerability, supply, insurance coverage and personal medical history all matter — but it is the headline finding.

Featured snippet: which loses more weight, Mounjaro or Ozempic?

In direct head-to-head data, tirzepatide (Mounjaro / Zepbound) produces approximately 5–6 percentage points more total body weight loss than semaglutide (Ozempic / Wegovy) over 68–72 weeks. Both drugs work; tirzepatide simply works somewhat harder on weight in most populations studied.

How they work

• Semaglutide is a GLP-1 receptor agonist. It mimics the natural gut hormone GLP-1, slowing gastric emptying, increasing insulin secretion when blood sugar is high, and reducing appetite signalling in the brain.
• Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates the GLP-1 receptor and also the GIP receptor, which appears to amplify weight loss and metabolic effects.

That extra GIP activity is the leading explanation for tirzepatide's slightly stronger effect on weight and HbA1c.

Weight loss compared

In the SURMOUNT-5 head-to-head, tirzepatide at the maximum tolerated dose produced an average total body weight loss of around 20%, vs around 14% for semaglutide. Real-world results are typically lower than trial results for both drugs, but the relative ranking holds.

Blood sugar (HbA1c) compared

In people with type 2 diabetes, both drugs reduce HbA1c substantially. Tirzepatide tends to reduce HbA1c by an additional 0.3–0.5 percentage points compared to semaglutide at comparable doses. Both routinely get patients to target. Track this in Blood Tests alongside fasting glucose and lipids — three months between labs is a reasonable cadence.

Side effects compared

Side effect profiles are broadly similar. Nausea, reflux, constipation and fatigue dominate for both drugs and tend to peak in the first weeks of each new dose. See Ozempic side effects for the full breakdown. In aggregate trial data there is no consistent winner on tolerability — individual response varies.

Dosing schedules compared

Both are weekly subcutaneous injections.

• Ozempic: start at 0.25 mg, then 0.5 mg, then 1 mg, then 2 mg.
• Wegovy (semaglutide for weight loss): 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg.
• Mounjaro / Zepbound: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.

The escalation calendar matters: most side effects appear at dose increases, so staying longer on a lower dose is often the right call if you are struggling.

Cost and access

List prices for both drugs are high in most markets. Coverage varies enormously: some plans cover the diabetes brands (Ozempic, Mounjaro) but not the weight-loss brands (Wegovy, Zepbound). Compounded semaglutide is widely available in some markets and was tightened in others — quality and dosing accuracy vary, and most clinicians prefer brand-name where possible.

What to track regardless of which drug you choose

This is where BodySynk earns its place. The most valuable thing on either drug is a single, continuous record of:

• weekly weight in Weight
• body measurements and Progress Photos
• side effects with severity in Symptoms & Notes
• dose history in Obesity Drugs
• food patterns in Nutrition
• bloodwork in Blood Tests
• a single shareable Health Summary for your next appointment

The full how-to is in How to track GLP-1 progress. When you hit a stall — almost everyone does — the data tells you whether it is a real plateau, a measurement artifact, or a behaviour drift; see GLP-1 weight loss plateaus.

When one might be a better fit than the other

This is a conversation for your prescriber, but practically:

• Higher weight-loss target. Tirzepatide tends to produce more.
• History of severe nausea on a GLP-1. Some patients find switching molecules helps; either direction is possible.
• Supply and cost. In many markets one is more reliably available or covered than the other.
• Comorbidities. Cardiovascular outcomes data is more mature for semaglutide. Both are evolving.

Deep dive: the GIP receptor

The key biological difference between tirzepatide and semaglutide is GIP. Glucose-dependent insulinotropic polypeptide is another gut hormone that, like GLP-1, is released in response to food. On its own, GIP did not look like a useful weight-loss target — early monotherapy trials were disappointing. But when paired with GLP-1 receptor activation, the combined effect appears to be greater than the sum of its parts: more satiety, better insulin response, and additional effects on fat tissue metabolism.

This is why tirzepatide tends to produce more weight loss than semaglutide at comparable doses. Whether it is truly "better" for any individual depends on tolerability, cost, supply and personal medical history.

How they behave week by week

Most users describe a similar week-to-week pattern on both drugs: noticeable appetite suppression within 2–5 days of the first injection, a steeper drop in food noise on tirzepatide, and a similar four-stage pattern of dose-related side effects (see Ozempic side effects).

Differences worth tracking:

• Speed of response. Tirzepatide users often report appetite changes sooner and more sharply.
• Reflux. Some patients find tirzepatide gentler on reflux, some find the opposite. This is highly individual.
• Late-week return of hunger. Tirzepatide clears slightly faster than semaglutide, so day 6–7 hunger can be more noticeable.

What the long-term outcome data shows

Both drugs have mature data on glycaemic outcomes and growing data on cardiovascular outcomes. Semaglutide has stronger cardiovascular outcomes data at this point in time. Tirzepatide's cardiovascular outcomes program is ongoing, with promising early signals.

For most patients, the practical question is not the cardiovascular outcomes study — it is the trajectory of weight, HbA1c, blood pressure, lipids and how you feel. Track all of these in ${APP.bloodwork} and ${APP.timeline}.

Switching between drugs

Switching is common and usually straightforward:

• Pause the current drug for one week
• Start the new drug at the lowest dose
• Re-escalate slowly

Most prescribers ask patients to log dose dates carefully during a switch in ${APP.obesity} — it makes the next conversation much easier.

Cost and supply realities in 2026

This changes quickly. Some markets have stable supply of all four brands (Ozempic, Wegovy, Mounjaro, Zepbound). Others still have intermittent supply on at least one. Compounded semaglutide is widely available in some markets, tightened in others; most clinicians prefer brand-name where possible because dosing accuracy and quality are more consistent.

How to choose with your prescriber

Good questions to bring to the consultation:

• What are realistic outcome expectations for me on each drug?
• Which is more reliably available and affordable for me?
• Do I have any history (gallbladder, pancreatitis, severe reflux, gastroparesis, thyroid history) that would steer the choice?
• How will we track progress and decide on dose escalations? Show the ${APP.summary} you intend to bring to every visit.

30 / 60 / 90 day comparison checklist

If you are evaluating either drug, set these checkpoints up front:

• Day 30 — baseline weight in ${APP.weight}, baseline measurements, baseline ${APP.photos}, baseline bloodwork in ${APP.bloodwork}.
• Day 60 — repeat measurements and photos, side-effect score in ${APP.symptoms}, food pattern audit in ${APP.nutrition}.
• Day 90 — repeat bloodwork, full ${APP.timeline} review with your prescriber, decide hold/escalate/switch.

Myths worth letting go

• "Mounjaro is just a stronger Ozempic." Different molecule, different mechanism — not a stronger dose of the same drug.
• "Switching means starting from scratch." Many people preserve progress through a switch if habits and tracking stay tight.
• "Whichever drug loses more weight is better for everyone." Tolerability, cost, supply and comorbidities all matter.

Frequently asked questions

Is Mounjaro stronger than Ozempic?

In head-to-head data, tirzepatide produces more weight loss and slightly more HbA1c reduction than semaglutide at comparable doses.

Can I switch from Ozempic to Mounjaro?

Yes, this is common — usually after a wash-out and starting Mounjaro at its lowest dose. Always with your prescriber.

Which has fewer side effects?

Aggregate trial data shows similar tolerability. Individual response varies; some people tolerate one better than the other.

Is Zepbound the same as Mounjaro?

Zepbound and Mounjaro are both tirzepatide; Zepbound is branded for weight loss, Mounjaro for type 2 diabetes.

How quickly will I see results?

Most people see early appetite changes within days. Meaningful weight change usually appears between weeks 4 and 12 and continues for many months.

Who should not start GLP-1 medication

GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro are prescription medications and are not appropriate for everyone. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disease such as gastroparesis, active pancreatitis, and during pregnancy or breastfeeding. If you take insulin or sulfonylureas you may need dose adjustments to avoid low blood sugar. None of the information here is medical advice — always talk to your Doctor Appointment before starting, changing or stopping any GLP-1 medication.

Side-by-side at a glance

| Feature | Ozempic / Wegovy (semaglutide) | Mounjaro / Zepbound (tirzepatide) | | --- | --- | --- | | Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist | | Average weight loss at 68 weeks | ~15% (Wegovy STEP trials) | ~20–22% (Mounjaro/Zepbound SURMOUNT trials) | | Typical dose schedule | Weekly, titrated 0.25 → 2.4 mg | Weekly, titrated 2.5 → 15 mg | | Common side effects | Nausea, reflux, constipation, fatigue | Same profile; some report less reflux, more burping | | HbA1c reduction in T2D | ~1.5–1.8% | ~2.0–2.4% | | Availability (2026) | Widely available | Improving but still patchy in some regions | | Approved brand for weight loss | Wegovy | Zepbound |

These figures are population averages from published trials — individual response varies widely, which is exactly why a long-term GLP-1 tracker matters more than a single headline number.

Practical tracking advice when switching drugs

Switching from semaglutide to tirzepatide (or back) is one of the most common GLP-1 decisions in 2026. Logging it cleanly in Obesity Drugs saves months of guesswork later:

1. Mark the last dose of the old drug and the first dose of the new one.
2. Reset your subjective baseline in Symptoms & Notes — energy, hunger, reflux, sleep — on the day of the switch.
3. Hold your usual Weight cadence; do not expect the trend to behave for 2–4 weeks.
4. Keep Blood Tests on the same schedule so the before/after comparison is honest.
5. Photograph yourself in Cosmetic & Photos the week of the switch.

Common mistakes when comparing the two

• Comparing peak loss on one drug to early loss on another. Twelve weeks on tirzepatide vs twelve months on semaglutide is not a fair comparison.
• Switching at the first plateau. Most plateaus are dose-driven, not drug-driven — read the GLP-1 plateau guide first.
• Ignoring side-effect profile differences. A drug that lets you sleep, eat protein and stay hydrated is the right drug, even if the trial numbers favour the other one.
• Stopping a working drug for social reasons. Cost, supply, or "I have heard Mounjaro is better" are real factors, but log the reason in BodyStory so future-you understands the decision.

Doctor discussion points

• Current weight trend and rate of change over the last 12 weeks.
• Side-effect severity on the current drug (numeric, from Symptoms & Notes).
• HbA1c, lipids and liver markers from your most recent Blood Tests.
• Realistic goal — total loss, maintenance, or metabolic control.
• Supply, cost and insurance reality for each drug.
• Plan for tapering or maintenance if you reach goal — see coming off Ozempic.

Real-world scenarios

A. Strong response to semaglutide, mild side effects, near goal weight. Usually no reason to switch. Hold and read the coming off Ozempic guide when you are ready to discuss maintenance.

B. Stalled on Wegovy 2.4 mg for 12+ weeks with good adherence. A switch to tirzepatide is a reasonable conversation — track the change carefully.

C. Intolerable reflux on semaglutide. Some people tolerate tirzepatide better; others do not. The only way to know is structured logging in Symptoms & Notes for 8–12 weeks.

D. Pre-diabetes, modest weight goal. Either drug works; choose on side-effect profile, cost and availability.

Extra FAQs

Is Mounjaro just a stronger Ozempic?

No. It targets a second receptor (GIP) as well as GLP-1, which changes the appetite and metabolic effect — not just the dose.

Can I take both?

No — they overlap mechanistically and stacking is not safe or evidence-based.

How long until I can compare results fairly?

At least 12 weeks on a stable maintenance dose of each. Anything shorter is noise.

Does switching reset side effects?

Often yes. Expect a fresh titration period with the new drug.

How BodySynk supports your GLP-1 treatment day to day

A GLP-1 medication only works as well as the routine around it. BodySynk is built to be that routine — a calm, private health memory that quietly captures what changes from week to week so you and your doctor can see the full picture, not a single weigh-in.

• Injections: log every dose, weekday and time in Obesity Drugs — see exactly when you escalated and how your body responded.
• Weight: Weight shows a smoothed 7-day trend that ignores daily noise from salt, sleep and cycle.
• Body measurements: waist, hip, chest and thigh entries reveal recomposition the scale misses.
• Progress photos: private side-by-side comparisons in Cosmetic & Photos make six-month changes obvious.
• Symptoms & side effects: Symptoms & Notes timestamps nausea, reflux, fatigue, mood and appetite so you can spot dose-day patterns.
• Bloodwork: upload labs to Blood Tests and watch HbA1c, lipids, ALT and kidney markers move across panels.
• Other medications: track interactions and adherence in Medications.
• Nutrition: scan or log meals in Nutrition without calorie shaming — the goal is protein, fibre and hydration patterns, not a number.
• Supplements: keep electrolytes, fibre, B12 and creatine in Supplements.
• Doctor visits: generate a one-page handout from Doctor Appointment covering dose, trend, side effects and questions.
• The story: every entry flows into BodyStory — a single chronological view of your treatment.

Pair it with the pillar guide to the best GLP-1 tracker to set the whole system up in under ten minutes.

Track it with BodySynk

Whichever you take, BodySynk gives you a single place to track outcomes — weight trend, side effects, bloodwork and progress photos.

BodySynk is a long-term health memory built for people on GLP-1 medication. Log your dose, weight, measurements, photos, side effects, meals and bloodwork in one place — and let the app surface patterns over weeks and months, not just one data point at a time. Read the full GLP-1 tracking guide to see how everything connects.

• Obesity Drugs — log Ozempic, Wegovy, Mounjaro, Zepbound and dose changes
• Weight — daily or weekly weight with smoothed trend lines
• Progress Photos — private side-by-side comparisons over time
• Symptoms & Notes — nausea, reflux, fatigue, mood, appetite
• Blood Tests — upload labs and watch markers move
• Health Summary — share a clear, doctor-ready summary in seconds

Related reading

• Best GLP-1 tracker app — the full pillar guide
• Ozempic side effects
• How to track GLP-1 progress
• Best foods on Ozempic